Lonza Houston’s Biotech Facility, Pearland, Texas, United States of America


Lonza Houston

Viral and cell therapy manufacturer Lonza Houston, along with City of Pearland and the Pearland Economic Development Corporation (PEDC), broke the ground on a new biotech facility for viral and immunotherapy development, and manufacturing in Pearland, Texas, US, on 29 March 2016.

The groundbreaking ceremony was attended by Pearland mayor Tom Reid, City Manager Clay Pearson, PEDC board member Brandon Dansby, state representative Ed Thompson, Lonza Houston site director Ricardo Jimenez, Lonza operations for emerging technologies SVP Stefan Troger, PEDC board chair Rushi Patel, and PEDC board members Reid Wendell and Lucy Stevener.

"The construction of the new biotech facility is expected to fulfil the city's long-lasting goal of establishing a broad spectrum of medical and life sciences organisation in the region."

The leadership from the City of Pearland and the Pearland Economic Development Corporation (PEDC) approved the construction of the Lonza's state-of-the-art biotech facility on 17 December 2015.

The construction of the new biotech facility is expected to fulfil the city's long-lasting goal of establishing a broad spectrum of medical and life sciences organisation in the region.

The construction on the facility is expected to be completed by the third quarter of 2017.

Lonza's biotech facility details

The state-of-the-art facility will be located on an 11-acre site on Kirby Drive in Pearland's Lower Kirby District. It is designed to accommodate office space, process development unit, quality control laboratories and fully segregated fill-and-finish suite.

The proposed facility will also contain independent modular clean rooms with a total capacity up to 2,000l scale production in single-use bioreactors.

The clean rooms will be designed to manufacture the cell therapy products to meet the growing demand for the products in the US and European markets.

The planned facility is expected to double the company's current capacity for the production of viral gene and virally modified therapeutics to create products for safer and healthier living.

The facility will initially generate more than 80 jobs and is expected to create more opportunities at a later stage in the fields of administration, manufacturing, process development and quality assurance.

Key players involved with Lonza's new facility

Lonza is building the new biotech facility in collaboration with Pinchal & Co., Creed Commercial Development, ARCO Design/Build, and CRB.

Marketing commentary

Lonza is a global leader and trusted supplier in the pharma & biotech and specialty ingredients markets. Headquartered in Basel, Switzerland, the company is focused on advance manufacturing, quality control systems, superior regulatory expertise, and research and development (R&D) capabilities.

The company's products and services include active pharmaceutical ingredients, stem cell therapies, drinking water sanitizers, vitamin B compounds, organic personal care ingredients, industrial preservatives and microbial control solution to combat viruses, bacteria and other dangerous pathogens. The company also provides agricultural services and products.